Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Medicaid Movantik Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentArizona Complete HealthPolicy AZ.CP.PMN.171

    Clinical Policy: Naloxegol (Movantik)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PMN.171 alerts

    Get alerted when Policy AZ.CP.PMN.171 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage of Movantik (naloxegol) for Arizona Medicaid members, primarily for opioid-induced constipation in adults receiving chronic opioid therapy. It specifies initial and continued-therapy criteria, documentation requirements, dosing limits, exclusions, and approval durations.

    Policy Summary
    PayerArizona Complete Health
    PolicyNaloxegol (Movantik) coverage
    Policy CodePolicy AZ.CP.PMN.171
    Change TypeAdministrative/reference update
    Effective DateSep 1, 2019
    Last ReviewOct 1, 2020
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation showing that all applicable approval criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    The 4Q 2020 annual review reported no significant changes and updated the references.

    The policy added Care1st branding and language specifying that the criteria also apply to Care1st.

    25 mg/dayMaximum covered daily dose
    18+ yearsMinimum age for initial approval
    6 monthsInitial approval duration
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Continuation approval duration
    3Required laxative classes

    Coverage Criteria and Exclusions

    Initial therapy: opioid-induced constipation

    Covered for opioid-induced constipation when ALL of the following are met.

    Initial opioid-induced constipation criteria

    • Clinical eligibility

      • ALL of the following

        • Member has a diagnosis of opioid-induced constipation.
        • Member is age 18 years or older.≥18 years
        • Member has taken opioids for at least 4 weeks for chronic pain not caused by active cancer.≥4 weeks
    • Required treatment failures

      • Member has failed one stimulant laxative while receiving opioid therapy, unless all agents in the class are contraindicated or clinically significant adverse effects occur.
      • Member has failed one osmotic laxative while receiving opioid therapy, unless all agents in the class are contraindicated or clinically significant adverse effects occur.
      • Member has failed one stool softener while receiving opioid therapy, unless all agents in the class are contraindicated or clinically significant adverse effects occur.
      • Member has failed Amitiza, unless it is contraindicated or clinically significant adverse effects occur.
    • Recent therapy and dose

      • Member has used one of the aforementioned laxative agents within the past 30 days, unless contraindicated.Within the past 30 days
      • The requested dose does not exceed 25 mg per day (one tablet per day).≤25 mg/day

    Continuation therapy: opioid-induced constipation

    Continued coverage for opioid-induced constipation requires ALL of the following.

    Continuation opioid-induced constipation criteria

    • Member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
    • Member continues to receive opioid therapy.
    • Member is responding positively to therapy.
    • If the request is for a dose increase, the new dose does not exceed 25 mg per day (one tablet per day).≤25 mg/day

    Continuation therapy: other diagnoses

    Continued coverage for other diagnoses or indications requires ONE of the following.

    ONE of

    • Member is currently receiving the medication through the Centene benefit and documentation supports a positive response to therapy.

      Approval duration is the duration of the request or 12 months, whichever is less.

    • The diagnosis is referred to the applicable off-label use policy for the relevant line of business when the diagnosis is not specifically listed among the indications for which coverage is not authorized.

      For Arizona Medicaid, refer to the applicable off-label use policy AZ.CP.PMN.53.

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy unless sufficient documentation of efficacy and safety supports coverage under the applicable Arizona Medicaid off-label use policy, AZ.CP.PMN.53.

    Movantik is contraindicated for members with known or suspected gastrointestinal obstruction or an increased risk of recurrent obstruction; concomitant use with strong CYP3A4 inhibitors, such as clarithromycin or ketoconazole; or a known serious or severe hypersensitivity reaction to Movantik or any of its excipients.

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Documentation Required

    Submit prior authorization documentation demonstrating that the member meets all applicable approval criteria for Movantik. Include clinical records supporting medical necessity.

    Step Therapy

    Document Amitiza Trial or Exception

    Document that the member has failed Amitiza (lubiprostone), unless it is contraindicated or caused clinically significant adverse effects. Prior authorization may be required for Amitiza.

    • Record the Amitiza trial, outcome, and dates of use.
    • If Amitiza was not used, document the contraindication or clinically significant adverse effects.
    Step Therapy

    Medication Overview

    Naloxegol (Movantik) is an opioid antagonist indicated for opioid-induced constipation in adults with chronic non-cancer pain. This includes chronic pain related to prior cancer or its treatment when frequent opioid dosage escalation is not required. The policy addresses members receiving chronic opioid therapy and requires failure of conventional laxative classes and Amitiza before initial approval.

    Key Terms

    Naloxegol (Movantik)
    MedicationNaloxegol (Movantik)
    Drug classOpioid antagonist
    IndicationTreatment of opioid-induced constipation in adults with chronic non-cancer pain
    Opioid-Induced Constipation (OIC)
    AbbreviationOIC
    DefinitionOpioid-induced constipation
    Covered populationAdult patients with chronic non-cancer pain receiving opioid therapy

    Initial Therapy

    Movantik initial therapy

    Initial therapy is covered for opioid-induced constipation when ALL of the following are met.

    Initial approval criteria

    • Member has a diagnosis of opioid-induced constipation.
    • Member is age 18 years or older.≥18 years
    • Member has taken opioids for at least 4 weeks for chronic pain not caused by active cancer.≥4 weeks
    • Required treatment failures

    Continuation Therapy

    Movantik continuation therapy

    Continued therapy is covered for opioid-induced constipation when ALL of the following are met.

    Continuation criteria

    • Member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
    • Member continues to receive opioid therapy.
    • Member is responding positively to therapy.
    • If the request is for a dose increase, the new dose does not exceed 25 mg per day (one tablet per day).≤25 mg/day

    Required Prior Therapies

    StepRequired therapyException or note
    1Failure of one stimulant laxative while receiving opioid therapy, such as bisacodyl or senna.Requirement may be waived if all agents in the class are contraindicated or clinically significant adverse effects are experienced.
    StepRequired therapyException or note
    2Failure of one osmotic laxative while receiving opioid therapy, such as lactulose or polyethylene glycol.Requirement may be waived if all agents in the class are contraindicated or clinically significant adverse effects are experienced.
    StepRequired therapyException or note
    3Failure of one stool softener while receiving opioid therapy, such as docusate.Requirement may be waived if all agents in the class are contraindicated or clinically significant adverse effects are experienced.
    StepRequired therapyException or note
    4Failure of Amitiza (lubiprostone).Requirement may be waived if Amitiza is contraindicated or clinically significant adverse effects occur. Prior authorization may be required for Amitiza.

    Dose and Quantity Limits

    Naloxegol (Movantik) Dose Limit
    Maximum covered dose25 mg per day
    Maximum quantityOne tablet per day
    Standard regimen25 mg orally once daily
    Dose adjustmentReduce to 12.5 mg once daily if 25 mg is not tolerated
    Policy Summary
    PayerArizona Complete Health
    PolicyNaloxegol (Movantik) coverage
    Policy CodePolicy AZ.CP.PMN.171
    Change TypeAdministrative/reference update
    Effective DateSep 1, 2019
    Last ReviewOct 1, 2020
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation showing that all applicable approval criteria are met.
    SourceLink
    On This Page
    Coverage Criteria and ExclusionsPrior Authorization and DocumentationMedication OverviewKey TermsInitial TherapyContinuation TherapyRequired Prior TherapiesDose and Quantity Limits

    Step 1: Stimulant Laxative

    Document failure of a stimulant laxative while the member was receiving opioid therapy, unless the entire class is contraindicated or clinically significant adverse effects were experienced.

    • Examples include bisacodyl and senna.
    • Record the agent, treatment dates, response, and reason for discontinuation or exception.
    Step Therapy

    Step 2: Osmotic Laxative

    Document failure of an osmotic laxative while the member was receiving opioid therapy, unless the entire class is contraindicated or clinically significant adverse effects were experienced.

    • Examples include lactulose and polyethylene glycol.
    • Record the agent, treatment dates, response, and reason for discontinuation or exception.
    Step Therapy

    Step 3: Stool Softener

    Document failure of a stool softener while the member was receiving opioid therapy, unless the entire class is contraindicated or clinically significant adverse effects were experienced.

    • Example: docusate.
    • Record the agent, treatment dates, response, and reason for discontinuation or exception.
    Step Therapy

    Step 4: Amitiza

    Document failure of Amitiza before requesting Movantik, unless Amitiza is contraindicated or not tolerated because of clinically significant adverse effects.

    • Include the Amitiza dose, duration, response, and reason for discontinuation or nonuse.
    • Prior authorization may be required for Amitiza.
    Documentation Required

    Clinical Documentation

    Submit clinical documentation supporting the request and demonstrating that the applicable approval criteria are met.

    • Office or chart notes
    • Laboratory results, when relevant
    • Other supporting clinical information
    Documentation Required

    Initial-Therapy Supporting Records

    For initial therapy, submit records documenting opioid-induced constipation and the member’s eligibility for treatment.

    • Diagnosis of opioid-induced constipation
    • Age 18 years or older
    • Opioid therapy for at least 4 weeks due to chronic pain not caused by active cancer
    • Prior treatment history, including failure or exceptions for a stimulant laxative, osmotic laxative, stool softener, and Amitiza
    • Use of one of the listed laxative agents within the past 30 days, unless contraindicated
    Documentation Required

    Continuation-Therapy Supporting Records

    For continuation therapy, submit records showing that treatment remains clinically appropriate and effective.

    • Member is currently receiving Movantik through the Centene benefit or previously met initial approval criteria.
    • Member continues to receive opioid therapy.
    • Member is responding positively to therapy; document response and clinical benefit.
    • For a dose increase, document that the requested dose does not exceed 25 mg per day (1 tablet daily).
    • Include prior approval details and the current treatment regimen.
    Denial Risk

    Non-FDA-Approved Indication

    Requests for indications other than opioid-induced constipation must meet the applicable coverage pathway and documentation requirements.

    • If the member is currently receiving the medication through the Centene benefit, document a positive response; approval is for the duration requested or 12 months, whichever is less.
    • If the diagnosis is not specifically listed as an authorized indication, refer to the applicable off-label use policy, including AZ.CP.PMN.53 for Arizona Medicaid.
    • Non-FDA-approved indications not addressed by this policy are not authorized unless sufficient efficacy and safety documentation supports coverage under the applicable off-label policy.
    Denial Risk

    Contraindications and Treatment Exclusions

    Screen for contraindications and document that none apply before submitting the request.

    • Known or suspected gastrointestinal obstruction or increased risk of recurrent obstruction
    • Concomitant use with strong CYP3A4 inhibitors, such as clarithromycin or ketoconazole
    • Known serious or severe hypersensitivity to Movantik or any excipient
    • No boxed warnings are reported
    Denial Risk

    Dose Limit: 25 mg per Day

    Movantik requests above the maximum allowed dose do not meet the dose criterion.

    • Maximum dose: 25 mg per day (1 tablet daily).
    • For opioid-induced constipation, the usual dose is 25 mg orally once daily; reduce to 12.5 mg once daily if not tolerated.
    • For continuation dose increases, the new dose must not exceed 25 mg per day.
    Failure of one stimulant laxative while on opioid therapy, unless all agents are contraindicated or clinically significant adverse effects occur.
  1. Failure of one osmotic laxative while on opioid therapy, unless all agents are contraindicated or clinically significant adverse effects occur.
  2. Failure of one stool softener while on opioid therapy, unless all agents are contraindicated or clinically significant adverse effects occur.
  3. Failure of Amitiza, unless contraindicated or clinically significant adverse effects occur.
  4. Member has used one of the listed laxative agents within the past 30 days, unless contraindicated.Within the past 30 days
  5. The dose does not exceed 25 mg per day (one tablet per day).≤25 mg/day
  6. Other-indication continuation

    For other diagnoses or indications, ONE continuation pathway must be met.

    ONE of

    • Member is currently receiving the medication through the Centene benefit and documentation supports a positive response to therapy.

      Approval duration is the duration of the request or 12 months, whichever is less.

    • The diagnosis is referred to the applicable off-label use policy for the relevant line of business when the diagnosis is not specifically listed among the indications for which coverage is not authorized.

      For Arizona Medicaid, refer to the applicable off-label use policy AZ.CP.PMN.53.